ArticleScientific reports2024

Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma.

Mingyuan Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.